Why Ionis Pharmaceuticals’ (IONS) 2026 Catalyst Pipeline Supported Leerink’s Higher Target

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is 1 of the best maturation stocks to bargain according to billionaires.

As of March 13, 2026, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) carried a Moderate Buy statement connected Wall Street. Based connected 21 expert targets, the mean terms people stood astatine $89.00, with a precocious people of $110.00 and a debased people of $39.00. Using the stock terms successful that March 13 snapshot, the mean people implied astir 25% upside.

Likoper/Shutterstock.com

The bullish stance came arsenic Ionis entered 2026 with a fuller commercialized and pipeline communicative than a elemental standing alteration mightiness suggest. On February 25, 2026, the institution reported full-year 2025 gross of $944 million, up 34% from 2024, helped by the commercialized motorboat of TRYNGOLZA and a $280 cardinal upfront outgo from Ono Pharmaceutical. Ionis besides said it expects 2026 gross of $800 cardinal to $825 cardinal connected a like-for-like ground and ended 2025 with $2.7 cardinal successful cash, currency equivalents, and short-term investments.

Management past added much discourse astatine capitalist conferences successful March. At the TD Cowen league connected March 2, 2026, Ionis said TRYNGOLZA had received precedence reappraisal for terrible hypertriglyceridemia, with a June 30, 2026, PDUFA date, and indicated that 2026 guidance for the merchandise could beryllium updated aft the archetypal quarter. At the Leerink league connected March 9, 2026, the institution said TRYNGOLZA generated $108 cardinal successful 2025 gross and projected U.S. highest income supra $2 billion. Ionis besides pointed to respective 2026 catalysts, including Phase 3 readouts tied to CARDIO-TTRansform and Novartis-partnered pelacarsen successful HORIZON. At the Barclays league connected March 11, 2026, absorption again described 2026 arsenic a transformational twelvemonth with aggregate launches, approvals, and late-stage readouts ahead.

Against that backdrop, Leerink expert Mani Foroohar maintained an Outperform standing connected March 3, 2026, and raised his terms people to $104 from $102.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is simply a biotechnology institution focused connected discovering and processing RNA-targeted medicines for superior diseases. The institution says its level is built astir advancing treatments crossed neurology, cardiology, and different specialty areas.

While we admit the imaginable of IONS arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.